UT-MD Anderson Cancer Center: Combination Immunotherapy Treatment Effective Before Lung Cancer Surgery
September 15, 2023
September 15, 2023
HOUSTON, Texas, Sept. 15 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Translational findings support combinations over single-agent therapy
* * *
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to resear . . .
* * *
Translational findings support combinations over single-agent therapy
* * *
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to resear . . .